Travere Therapeutics (TVTX) Receivables - Other (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Receivables - Other came in at $1.2 million in Q1 2026, down 42.86% YoY from $2.1 million in Q1 2025, and down 7.69% on a QoQ basis from $1.3 million in Q4 2025.
Travere Therapeutics (TVTX) Receivables - Other (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 9 years of Receivables - Other data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Receivables - Other fell 42.86% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 42.86% YoY) and the FY2025 annual result came in at $1.3 million, down 43.48% from the prior year.
- Receivables - Other eased to $1.2 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $4.6 million in Q4 2023 to a low of $1.2 million in Q1 2026.
- A 5-year average of $2.4 million and a median of $2.2 million in 2024 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2023 — Receivables - Other soared 142.11% — and 2024, when it sank 50.0%.
- Tracing TVTX's Receivables - Other over 5 years: stood at $1.9 million in 2022, then soared by 142.11% to $4.6 million in 2023, then slumped by 50.0% to $2.3 million in 2024, then sank by 43.48% to $1.3 million in 2025, then slipped by 7.69% to $1.2 million in 2026.
- The last three Receivables - Other figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Mar 31, 2024 | 3.80 Mn |